News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Chimeric Therapeutics.
RELATED STOCKHEAD STORIES
News
ASX Small Caps Lunch Wrap: Who got the worst kind of welcome home last week?
Health & Biotech
ASX Health Stocks: Chimeric leaps 65pc on Phase1A results, Immutep over 12pc on Phase 2
News
Top 10 at 11: This morning is all about lithium, graphite and the fight against Glioblastoma
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Bad week for benchmark; signals of a Sino solution, however, if Albo is able
Explainers
ASX cancer stocks guide: Here’s everything you need to know
Health & Biotech
ASX Health Stocks: Starpharma jumps 30pc after cancer drug helps enable ‘100 per cent’ control rate
News
Top 10 at 11: This morning’s early gains are brought to you by lithium, nickel and… almonds.
News
Closing Bell: ASX runs out of puff, closes down 1.5% as energy sector weighs on markets
Experts
CRITERION: The ASX cancer fighters with a sting in their treatment tails
Health & Biotech
ASX Health Stocks: CardieX jumps 16pc after FDA clearance; 3 other ASX biotechs to commence trials
Health & Biotech
ASX Health Stocks: Firebrick to start Phase 3 trial on common cold spray, MGC Pharma surges 30pc on FDA listing
Health & Biotech
ASX Health Stocks: UBI jumps 10pc on Xprecia Prime study; Neuren gets another green light from FDA
IPO Watch
Most ASX growth stocks have taken a beating in 2022. Are there oversold IPOs among them?
Investor Guides
Investor Guide: Health & Biotech FY2023
Stockhead TV
CAR-T therapies are leading the race to cure cancer
Health & Biotech